Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-12
2011-07-12
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S772000, C514S772600, C514S773000, C514S777000, C514S781000, C514S783000, C514S952000, C514S970000, C424S450000, C424S489000, C424S490000, C424S493000, C424S494000, C424S495000
Reexamination Certificate
active
07977369
ABSTRACT:
Methods for treating bladder cancer comprising intravesicular administration of a stabilized pharmaceutical formulation comprising 5-(1-aziridinyl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methyl-1H-indole-4,7-dione (EO9). More specifically, the stabilized pharmaceutical formulation is instilled in the bladder for a time sufficient to treat the cancer.
REFERENCES:
patent: 3993754 (1976-11-01), Rahman et al.
patent: 4671954 (1987-06-01), Goldberg et al.
patent: 4871542 (1989-10-01), Vilharot
patent: 5079257 (1992-01-01), Speckampt et al.
patent: 5216011 (1993-06-01), Paborji et al.
patent: 5292516 (1994-03-01), Viegas et al.
patent: 5346703 (1994-09-01), Viegas et al.
patent: 5405622 (1995-04-01), Vernice et al.
patent: 5744166 (1998-04-01), Illum
patent: 5749845 (1998-05-01), Hildebrand et al.
patent: 5814330 (1998-09-01), Putterman et al.
patent: 5843156 (1998-12-01), Slepian et al.
patent: 5942209 (1999-08-01), Leavitt et al.
patent: 5993846 (1999-11-01), Friedman et al.
patent: 6005020 (1999-12-01), Loomis
patent: 6039967 (2000-03-01), Ottoboni et al.
patent: 6087396 (2000-07-01), Roberts
patent: 6123965 (2000-09-01), Jacob et al.
patent: 6156348 (2000-12-01), Santos et al.
patent: 6171610 (2001-01-01), Vacanti et al.
patent: 6207180 (2001-03-01), Ottoboni et al.
patent: 6894071 (2005-05-01), Nuijen et al.
patent: 0331635 (1989-09-01), None
patent: 0338879 (1989-10-01), None
patent: 0393575 (1990-10-01), None
patent: 0426483 (1991-05-01), None
patent: 0501523 (1992-09-01), None
patent: 0642797 (1995-03-01), None
patent: 354151134 (1979-11-01), None
patent: 360163621 (1986-08-01), None
patent: 361189215 (1986-08-01), None
patent: 407215843 (1995-08-01), None
patent: 02000256182 (2000-09-01), None
patent: 02001010951 (2001-01-01), None
patent: 8706227 (1987-10-01), None
patent: 9726864 (1997-07-01), None
patent: 9912548 (1999-03-01), None
patent: 9965483 (1999-12-01), None
patent: 0033816 (2000-06-01), None
Cliff, A.M. et al., “The effect of fasting or desmopressin before treatment on the concentration of mitomycin C during intravesical administration,” BJU International, vol. 86, pp. 644-677 (2000).
Medline abstract 1987238242 (1987).
Choudry el al., “A Novel Strategy for NQ01 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) Mediated Therapy of Bladder Cancer Based on the Pharmacological Roperties of E09”, British Journal of Cancer, 2001, pp. 1137-1146, vol. 85, No. 8.
Schellens et al., “Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09”, Journal of the National Cancer Institute, 1994, pp. 906-912, vol. 86, No. 12.
Robertson et al. “Factors affecting sensitivity to E09 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia”, European Journal of Cancer, 1994, pp. 1013-1019, vol. 30A, No. 7.
Dong Li et al., “Distribution of DT-diaphorase and cytochrome P450 reductase in human bladder tissues and tumors”, Proceedings of the American Association for Cancer Research Annual, 2001, p. 648, vol. 42.
Kantoff et al., “Bladder Cancer, Neoplasms of the Genitourinary Tract”, Chapter 107, pp. 1543-1558.
Cummings et al., “Pharmacological and biochemical determinants of the antitumor activity of the indoloquinone E09”, Biochemical Pharmacology, 1998, pp. 253-260, vol. 55, No. 3.
Nicolaus, “Symbiotic Approach to Drug Design, Decision Making in Drug Research”, 1983, pp. 173-186.
Chemical Abstracts 120: 62141, 1994.
Workman, P., “Enzyme directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinine anticancer drugs and quinine metabolizing enzymes, particularly NQO1.” Oncol. Res., 1994, (10/11) 6:461-475.
Medline Abstract 92362735, 1992.
Medline Abstract 2001071878 (Entered Medline Jan. 4, 2001).
De Vries J.D. et al., A systematic study on the chemical stability of the novel indoloquinone antitumor agent EO9; abstract, International Journal of Pharmaceutics, 1993.
De Vries, J.D., et al., Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9; abstract, Cancer Chemotherapy and Pharmacology, 1994, vol. 34.
Bradford M.M., “A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding.” Anal. Biochem., 1976, 72:248-254.
Butler, J., et al., “The autooxidation of reduced forms of EO9.” Free. Rad. Res., 1996, 25(2):141-148.
Connors, T.A., “Bioreductive agents, hypoxic cells and therapy.” Eur. J. Cancer, 1996, 32A(11):1833-1834.
Cummings, J., et al., “Enzymology of MMC metabolic activation in tumor tissue. Implications for enzyme directed bioreductive drug development.” Biochem. Pharmacol., 1998, 56:405-414.
De Ascentiis, A., et al., “Mucoadhesion of poly(2-hydroxyethyl methacrylate) is improved when linear poly(ethylene oxide) chains are added to the polymer network.” 1995, Journal of Controlled Release, vol. 33, pp. 197-201.
Dirix, L.Y., et al., “E09 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the early clinical studies group.” Eur. J. Cancer, 1996, 32A(11):2019-2022.
Fitzsimmons, S.A., et al., “Reductase enzyme expression across the national Cancer Institute tumor cell line panel: Correlation with sensitivity to MMC and E09.” J. Nat. Cancer Inst., 1996, 88(5):259-269.
Gutierrez, P.L., “Mechanism of bioreductive alkylation. The example of diazaquinone (AZQ).” Free Radical Bio. Med., 1989, 6:405-445.
Hendriks, H.R., et al., “E09: A novel bioreductive alkylating indoloquinone with preferential solid tumor activity and lack of bone marrow toxicity in preclinical models.” Eur. J. Cancer, 1993, 29A(6):897-906.
Herr, H.W., “Intravesical therapy—a critical review.” Urol. Clin. N. Am., 1987, 14(2):399-404.
Hodnick, W.F., et al., “Measurement of dicumarol sensitive NADPH: (menadione cytochrome c) oxidoreductase activity results in an artificial assay of DT-diaphorase in cell sonicates.” Anal. Biochem., 1997, 252:165-168.
Kennedy, A.S., et al., “Proliferation and hypoxia in human squamous cell carcinoma of the cervix: First report of combined immunohistochemical assays.” Int. J. Radiat. Oncol. Biol. Phys., 1997, 37(4):897-905.
Kuin, A., et al., “Potentiation of anti-cancer activity at low intratumoural pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).” Br. J. Cancer, 1999, 79(5/6):793-801.
Laviada, I.D., et al., “Phosphatidylcholine-phospholipase C mediates the induction of nerve growth factor in cultured glial cells.” FEBS Letters, 1995, 364:301-304.
Li, D., et al., “Distribution of DT-diaphorase and cytochrome P450 reductase in human bladder tissues and tumors.” Proceedings of the American Association for Cancer Research Annual Meeting, Mar. 2001, 42:648.
Maffezzini, M., et al., “Up-front chemotherapy for low stage low grade recurrent bladder cancer.” L. Urol., 1996, 155:91-93.
Maliepaard, M. et al., “Indoloquinone E09: DNA interstrand cross linking upon reduction by DT-diaphorase or xanthine oxidase.” Br. J. Cancer, 1995, 71:836-839.
Malkinson, A.M., et al., “Elevated NQO1 activity and messenger RNA content in human non small cell lung carcinoma—Relationship to the response of lung tumor xenografts to MMC.” Cancer Res., 1992, 52(12):4752-4757.
Mossoba, M.M., et al., “Mechanism for the reductive activation of diazaquinone.” J. Pharm. Sci., 1985, 74 (12):1249-1254.
Newling, D., “Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU group.” Br. J. Cancer, 1990, 61:497-499.
Oosterlink, et al., “A prospective European Organization for Research and Tr
Beijnen Jos H.
Nuijen Bastiaan
Pfadenhauer Ernie
Cullman Louis C.
K&L Gates LLP
Pak John
Spectrum Pharmaceuticals Inc.
Stathakis Dean G.
LandOfFree
Medical compositions for intravesical treatment of bladder... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medical compositions for intravesical treatment of bladder..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical compositions for intravesical treatment of bladder... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2702632